scholarly article | Q13442814 |
P50 | author | Christian H. Lindh | Q42918326 |
Daniel Mucs | Q63378323 | ||
P2093 | author name string | Ying Li | |
Kristina Jakobsson | |||
Tony Fletcher | |||
Kristin Scott | |||
Pia Tallving | |||
P2860 | cites work | Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia | Q24633826 |
Two-year follow-up biomonitoring pilot study of residents' and controls' PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany | Q34116656 | ||
Perfluoroalkyl acids: a review of monitoring and toxicological findings | Q34630884 | ||
Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers | Q34680365 | ||
Tracking the pathways of human exposure to perfluorocarboxylates. | Q35001255 | ||
Drug transport by Organic Anion Transporters (OATs). | Q38030260 | ||
Perfluorooctane sulfonate: a review of human exposure, biomonitoring and the environmental forensics utility of its chirality and isomer distribution | Q38366490 | ||
Per- and polyfluoroalkyl substances in human serum and urine samples from a residentially exposed community | Q38711850 | ||
Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. | Q39360818 | ||
Human detoxification of perfluorinated compounds | Q42973627 | ||
Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model | Q44550012 | ||
A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans | Q46212335 | ||
Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives | Q48431394 | ||
Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000-2010. | Q50511791 | ||
Blood serum concentrations of perfluorinated compounds in men from Greenlandic Inuit and European populations. | Q51794582 | ||
Contribution of Direct and Indirect Exposure to Human Serum Concentrations of Perfluorooctanoic Acid in an Occupationally Exposed Group of Ski Waxers. | Q53080615 | ||
Differences in the isomer composition of perfluoroctanesulfonyl (PFOS) derivatives | Q79964917 | ||
Enhanced elimination of perfluorooctane sulfonic acid by menstruating women: evidence from population-based pharmacokinetic modeling | Q88107216 | ||
P433 | issue | 1 | |
P921 | main subject | drinking water | Q7892 |
P304 | page(s) | 46-51 | |
P577 | publication date | 2017-11-13 | |
P1433 | published in | Occupational and Environmental Medicine | Q7075795 |
P1476 | title | Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water | |
P478 | volume | 75 |
Q92673149 | Adverse Maternal, Fetal, and Postnatal Effects of Hexafluoropropylene Oxide Dimer Acid (GenX) from Oral Gestational Exposure in Sprague-Dawley Rats |
Q90113647 | Application of the Key Characteristics of Carcinogens to Per and Polyfluoroalkyl Substances |
Q90310069 | Associations between perfluoroalkyl substances and serum lipids in a Swedish adult population with contaminated drinking water |
Q99613125 | Chemical Characterization of a Legacy Aqueous Film-Forming Foam Sample and Developmental Toxicity in Zebrafish (Danio rerio) |
Q62387081 | Childhood perfluoroalkyl substance exposure and executive function in children at 8 years |
Q94567957 | Concentration of selected liver enzymes across the stages of glomerular function: the associations with PFOA and PFOS |
Q93123912 | Derivation of a chronic reference dose for perfluorohexane sulfonate (PFHxS) for reproductive toxicity in mice |
Q89836896 | Dietary characteristics associated with plasma concentrations of per- and polyfluoroalkyl substances among adults with pre-diabetes: Cross-sectional results from the Diabetes Prevention Program Trial |
Q91832552 | Dynamics of PCB exposure in the past 50 years and recent high concentrations in human breast milk: Analysis of influencing factors using a physiologically based pharmacokinetic model |
Q93000711 | Early pregnancy serum levels of perfluoroalkyl substances and risk of preeclampsia in Swedish women |
Q90362060 | Endocrine Disruptors in Water and Their Effects on the Reproductive System |
Q95836430 | Estimating Environmental Hazard and Risks from Exposure to Per- and Polyfluoroalkyl Substances (PFAS): Outcome of a SETAC Focused Topic Meeting |
Q60126454 | Evaluation and Management Strategies for Per- and Polyfluoroalkyl Substances (PFASs) in Drinking Water Aquifers: Perspectives from Impacted U.S. Northeast Communities |
Q89349832 | Exposure to perfluoroalkyl substances and associations with serum thyroid hormones in a remote population of Alaska Natives |
Q91948873 | Interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics and application to health-based criteria |
Q90356625 | Intrauterine exposure to perfluorinated compounds and overweight at age 4: A case-control study |
Q91961959 | Maternal serum levels of perfluoroalkyl substances in early pregnancy and offspring birth weight |
Q59156231 | Menstrual cycle characteristics as determinants of plasma concentrations of perfluoroalkyl substances (PFASs) in the Norwegian Mother and Child Cohort (MoBa study) |
Q49599814 | Oral contraceptive use as a determinant of plasma concentrations of perfluoroalkyl substances among women in the Norwegian Mother and Child Cohort (MoBa) study |
Q93350965 | Per and polyfluoroalkyl substances (PFAS) blood levels after contamination of a community water supply and comparison with 2013-2014 NHANES |
Q100444139 | Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research |
Q89134221 | Per- and polyfluoroalkyl substances impact human spermatogenesis in a stem-cell-derived model |
Q64072217 | Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation |
Q59800731 | Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes |
Q99592078 | Perfluoroalkyl substances are associated with elevated blood pressure and hypertension in highly exposed young adults |
Q90633512 | Perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) acutely affect human α1β2γ2L GABAA receptor and spontaneous neuronal network function in vitro |
Q97526919 | Pregnancy-induced changes in serum concentrations of perfluoroalkyl substances and the influence of kidney function |
Q62387101 | Prenatal and childhood exposure to perfluoroalkyl substances (PFAS) and measures of attention, impulse control, and visual spatial abilities |
Q64128838 | Prenatal and childhood exposure to poly- and perfluoroalkyl substances (PFAS) and cognitive development in children at age 8 years |
Q98729995 | Recent US State and Federal Drinking Water Guidelines for Per- And Polyfluoroalkyl Substances (PFAS) |
Q93160224 | Reducing exposure to high levels of perfluorinated compounds in drinking water improves reproductive outcomes: evidence from an intervention in Minnesota |
Q62086877 | Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food |
Q58701478 | Rubella immunity and serum perfluoroalkyl substances: Sex and analytic strategy |
Q97556479 | Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl Acids after Ceasing Exposure from Drinking Water Contaminated by Firefighting Foam |
Q89754498 | Serum Levels of Perfluoroalkyl Substances (PFAS) in Adolescents and Young Adults Exposed to Contaminated Drinking Water in the Veneto Region, Italy: A Cross-Sectional Study Based on a Health Surveillance Program |
Q92109687 | Toxicokinetics of perfluorobutane sulfonate (PFBS), perfluorohexane-1-sulphonic acid (PFHxS), and perfluorooctane sulfonic acid (PFOS) in male and female Hsd:Sprague Dawley SD rats after intravenous and gavage administration |
Search more.